Literature DB >> 17669967

Coronary artery dissection, combined aortic valve replacement and coronary bypass grafting in osteogenesis imperfecta.

M J Eskola1, K O Niemelä, P R Kuusinen, M R Tarkka.   

Abstract

Osteogenesis imperfecta is an inherited connective tissue disorder. Aortic root dilation, aortic insufficiency and mitral valve prolapse are uncommon cardiovascular manifestations of osteogenesis imperfecta. Cardiac surgery in patients with osteogenesis imperfecta involves a high risk of complication rate. We report a case of coronary artery dissection induced by coronary angiogram in a patient with osteogenesis imperfecta and severe aortic regurgitation. In this case, the dissection of a coronary artery was not completely sealed by coronary stenting, and followed by successful combined aortic valve replacement and coronary artery bypass grafting on an emergency basis.

Entities:  

Year:  2002        PMID: 17669967     DOI: 10.1016/s1569-9293(02)00060-9

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  4 in total

1.  Osteogenesis imperfecta, multiple intra-abdominal arterial dissections and a ruptured dissecting-type intracranial aneurysm.

Authors:  C C Matouk; A Hanbidge; D M Mandell; K G Terbrugge; R Agid
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

2.  Premature Atherosclerosis and Drug Eluting Stent Restenosis in an Adult with Osteogenesis Imperfecta.

Authors:  Mutlu Gungor; Mustafa Aparci; Ali C Özer
Journal:  Int J Angiol       Date:  2016-02-12

3.  Case report: osteogenesis imperfecta, internal mammary artery graft & nitinol clips.

Authors:  Ludovic Melly; Anne-Sophie Dincq; Claude Hanet; Benoît Rondelet
Journal:  J Cardiothorac Surg       Date:  2017-12-19       Impact factor: 1.637

4.  Cardiovascular involvement in children with osteogenesis imperfecta.

Authors:  Hamdollah Karamifar; Homa Ilkhanipoor; Gholamhossein Ajami; Zohreh Karamizadeh; Gholamhossein Amirhakimi; Ali-Mohammad Shakiba
Journal:  Iran J Pediatr       Date:  2013-10       Impact factor: 0.364

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.